WillItSurvive
Pharma and healthcare groups · United States

Becton Dickinson

bd.com ↗

Maker of syringes, IV pumps, and hospital dispensing systems used in most US hospitals.

Defensible for now
Assessed 20 July 2026 · Evidence as of 20 July 2026
Real protection, with named pressure against it.
On the recordSince 20 July 2026 · Checkable from August 6, 2026 · Every call on the record Checkpoint: Q3 FY2026 earnings call, plus continued Arizona federal court litigation activity on Alaris/Bard devices
The call

BD's hardware sits inside hospital walls where AI and rivals both struggle to reach, but recalls and lawsuits are the thing actually chipping at it right now.

Becton Dickinson makes syringes, IV systems, and medication-management software that hospitals depend on daily. It is hard to replace because hospitals have invested years training staff on BD equipment, regulators have approved it after years of testing, and no competitor has the scale or trust to unseat it quickly. The catch is a string of product recalls (Alaris pumps, ChloraPrep disinfectant, vascular devices) plus active lawsuits in Arizona federal court that could balloon into a major class action by mid-2026, which could drag on the stock price even if the company survives fine operationally.

Why
01
AI pressure: None apparent. AI shows up as a search layer on top of Pyxis dispensing cabinets, not as something that replaces the cabinets or the needles. Could AI do the core job? Unlikely.
02
Bigger players: Medtronic, Baxter, Boston Scientific, Abbott, J&J, Cardinal Health. Same regulated, hospital-embedded peers compete for the next contract cycle, but none has shipped a rival to swap out installed Pyxis or vascular-access systems. Could a giant copy it? No, they are blocked.
03
What protects it. FDA clearances plus 3 million connected devices already wired into hospital pharmacies and supply rooms that are costly to rip out.
What would change this call
Outcome of Arizona federal Alaris/Bard suits (Mitchell, Reeves, Smith, Jones, Roberts v. BD) by mid-2026. Would show whether litigation stays contained or escalates toward MDL-scale liability.
Whether another BD product recall is announced within 4-6 quarters after Alaris and ChloraPrep. Would show whether quality-system failures are a pattern rather than isolated events.
Q3 FY26 earnings (Aug 6, 2026) and whether Waters-related EPS accretion guidance of +200bps holds. Would show whether post-split integration is landing cleanly or slipping.
Key numbers
  • FY2025 revenue $21.84B, up 7.7% adjusted (2025-09-30)
  • Pyxis systems run 9.8M transactions/day on 3M devices (2025-10-20)
  • Market cap about $43.6B (2026-07-20)
Named risks
  • Alaris and Bard product liability litigation escalating toward MDL-scale consolidation, Arizona dockets active through June-July 2026. Severity: high
  • Recurring recalls (Alaris bezel kit, ChloraPrep June 2026) signal quality-system pattern, not isolated incident. Severity: high
  • SEC administrative distribution plan for the $175M settlement still unresolved into 2026. Severity: medium
  • Waters transaction integration and promised +200bps EPS accretion not yet confirmed in results. Severity: medium
  • China market and vaccine revenue headwinds flagged by management as FY26 growth risks. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
MedtroniccontestingFaces same regulatory and manufacturing barriers as BD in infusion and vascular devices, no share shift reported as of 2026-07
Baxter InternationalcontestingPeer in infusion/medication management, no RFP wins against Pyxis reported as of 2026-07
Johnson & JohnsoncontestingBD hired J&J Vision executive Peter Menziuso to lead BD Interventional, effective June 1, 2026
Waters Corporationlosing toBD divested its Biosciences and Diagnostic Solutions unit to Waters, deal closed 2026-02-09, ceding that market to combined entity
Questions people ask
Is Becton Dickinson profitable in 2026?
BD posted FY2025 net income of $1.68 billion on $21.84 billion revenue (year ended Sept 30, 2025). In fiscal Q2 2026 (ended March 31, 2026), adjusted EPS was $2.90 but GAAP EPS showed a $(0.13) loss, largely tied to costs from the Waters spin-off completed Feb 9, 2026.
Could AI replace Becton Dickinson?
No. BD's core products are physical hardware, infusion pumps, catheters, syringes, embedded in regulated hospital workflows with FDA clearances. AI (Incada, Pyxis Pro, launched Oct 2025) is layered on top as an analytics ingredient, not a substitute for manufacturing or clinical device use.
Who owns Becton Dickinson?
BD is publicly traded on the NYSE under ticker BDX with no controlling parent, market cap approximately $43.6 billion as of July 20, 2026. It restructured Feb 9, 2026 after combining its Biosciences and Diagnostic Solutions unit with Waters Corporation, leaving BD shareholders holding about 39.2% of the combined Waters entity.
Who is Becton Dickinson's biggest competitor?
No single rival directly threatens BD's core Pyxis medication management or vascular access share as of 2026. Peers like Medtronic, Baxter, Boston Scientific, Abbott and J&J face the same regulatory and manufacturing scale barriers, making it a stable oligopoly rather than active share loss.
Did Becton Dickinson spin off part of its business?
Yes. BD combined its Biosciences and Diagnostic Solutions business, valued at $18.8 billion, with Waters Corporation in a deal announced July 14, 2025 and closed February 9, 2026. BD received $4 billion cash and shareholders got about 0.135 Waters shares per BD share held.
Is Becton Dickinson facing major lawsuits in 2026?
Yes. Multiple product-liability suits over Alaris infusion pumps and Bard vascular access devices were filed in Arizona federal court through June and July 2026 (including Mitchell, Reeves, Smith, Jones and Roberts v. BD), with potential to consolidate into larger multidistrict litigation.
Timeline
  • 2026-07-09BD announces Q3 FY2026 earnings date of August 6, 2026
  • 2026-06-30New Alaris/Bard product liability suit (Mitchell v. BD) filed in Arizona federal court
  • 2026-06-06Nationwide recall of ChloraPrep/FREPP antiseptic applicator lots for microbial contamination
  • 2026-05-18Peter Menziuso named EVP and President of BD Interventional, from J&J Vision
  • 2026-05-07BD reports fiscal Q2 2026 results: $4.7B revenue, GAAP EPS loss of $(0.13); Vitor Roque named CFO
  • 2026-04-01AI-enabled Pyxis Pro dispensing system and Incada platform launched in Europe
  • 2026-02-09BD completes combination of Biosciences and Diagnostic Solutions business with Waters Corporation
  • 2026-01-23BD releases Research Cloud 7.0 with AI-powered Horizon Panel Maker tool
  • 2025-10-20BD launches Incada Connected Care Platform and Pyxis Pro in the US
  • 2025-07-14Waters Corporation announces definitive agreement to combine with BD's BDS unit
Revision history
20 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificEli Lilly
More in Pharma and healthcare groups →
Sources